Author Archives for Adeline Chauvigné

Pherecydes Pharma is adding to its patent portfolio with two new patents granted in the United States

4 November 2025

Pherecydes Pharma, a biotechnology company specialized in precision phagotherapy designed to fight resistant and/or complex bacterial infections, recently announced the... View Article

Thermo Fisher Scientific acquires viral vector manufacturing business from Novasep

4 November 2025

Thermo Fisher Scientific Inc., the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services... View Article

The latest edition of the Panorama France HealthTech produced by France Biotech

4 November 2025

Faced with a health crisis of historic proportions and the related unprecedented challenges, the healthcare sector is once again demonstrating... View Article

OSE Immunotherapeutics enters a loan agreement of up to €25 Million with the European Investment Bank

4 November 2025

This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high... View Article

New member | Orléans Val de Loire Technopole

4 November 2025

Orléans Val de Loire Technopole is an association created in 1988. As a key actor in the field of innovation,... View Article

New member | CNAM Pays de la Loire

4 November 2025

Supervised by the minister for Higher Education, the Cnam is a public scientific, cultural and professional institution, classed as a... View Article

BIG DATA | “Ouest Datahub”, the first European platform for hospital data, created by GCS HUGO

4 November 2025

The first hospital data platform in Europe, Ouest Datahub will group anonymized data from six hospitals engaged in medical research.... View Article

France’s Grand Ouest region, working together to exit the health crisis

4 November 2025

Right at the very beginning of the health crisis in March 2020, members of the Atlanpole Biotherapies cluster found themselves... View Article

#Coronavirus | XAV-19 – a national research priority

4 November 2025

THE POLYCOR CLINICAL TRIAL HAS BEEN LABELLED A “NATIONAL RESEARCH PRIORITY” The #POLYCOR clinical trial that is currently studying the... View Article

Valneva commences manufacturing of its inactivated, adjuvanted COVID-19 vaccine, completes Phase 1/2 study recruitment

4 November 2025

Vaccine production initiated to optimize timeline for potential deliveries Phase 1/2 clinical study now fully enrolled; initial data read out... View Article